Create a Profile
Get In Touch Mobile
Principal Investigator shares thoughts on TrueBinding Alzheimer’s trial
TrueBinding recently released results of a Phase 1b/2 trial for TB006, which showed improvements for patients with mild to severe Alzheimer’s Disease.
One of our valued primary investigators, Dr. Marshall Nash, participated in the trial and provided his feedback for the company’s findings release. Accel is very proud to be part of these results, and we look forward to working with TrueBinding to see what comes next for TB006.
Read complete TrueBinding-Topline-Release
Ready to be part of healthcare history? Find the right clinical trial for you.